We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Creo Medical Group Plc | CREO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 34.50 | 07:40:02 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 34.50 | 34.50 | 34.50 | 34.50 |
| Industry Sector |
|---|
| HEALTH CARE EQUIPMENT & SERVICES |
| Top Posts |
|---|
Posted at 29/3/2024 11:47 by dr biotech One investor implies they will be taken out by intuitive |
Posted at 12/3/2024 14:11 by dr biotech But it was at an investor conference though. I've never been to one - seemed like 100 PI's, not sure how many of them would be looking to invest or how much, a chance for PR though. |
Posted at 12/3/2024 12:43 by hatfullofsky Yes I would have expected it to at least have moved to - in development.In this investormeet presentation from 12/09/23 https://www.investor |
Posted at 08/2/2024 19:40 by cyberbub Someone needs to tell the company ASAP then, as it may be putting investors off. They seem to have missed it! |
Posted at 24/1/2024 08:44 by wan J&J expects strong procedure volumes in 2024After reporting growth for its procedure-based units in the fourth quarter, J&J forecast surgery volumes to be above pre-pandemic levels this year. Published Jan. 23, 2024 The company reiterated its guidance of 5%-6% operational sales growth and the goal for new products to generate one-third of revenue by 2027, both of which were given during its December investor day. J&J ended the year with several developments in competitive and growing medtech markets, including an updated timeline for Ottava, its soft tissue surgical robot to take on Intuitive Surgical’s da Vinci system Full story - |
Posted at 23/1/2024 08:05 by wan Two companies on Creo investor minds -3 bellwether companies to watch as medtech earnings season begins J&J, Intuitive Surgical and Abbott kick off this week with fourth-quarter reports. Published Jan. 22, 2024 RBC Capital Markets analysts were similarly upbeat, writing about “positive momentum exiting 2023 for both procedure volumes and capital spending” in a note to investors last week. A clearer picture of how the medtech industry fared in the fourth quarter and last year, and how companies expect to perform across 2024, will begin to emerge when J&J and Intuitive report results on Tuesday. Meanwhile, Abbott will report on Wednesday morning. Here, we preview what to look out for in the first week of earnings for the industry: Full story - |
Posted at 12/1/2024 07:45 by wan Intuitive is guiding for growth in procedures, robotic placements, and revenues -Intuitive CEO: Strong robot placements offset bariatric surgery slowdown Speaking at the J.P. Morgan Healthcare Conference, CEO Gary Guthart said the robotics company is also seeing strong growth in general surgeries. Published Jan. 11, 2024 the robotic surgery leader is also seeing strong system placements and growth in general surgeries, CEO Gary Guthart told investors at the J.P. Morgan Healthcare Conference in San Francisco. The company preannounced that overall procedures assisted by its da Vinci robot grew 21% in the fourth quarter, above analysts’ expectations. The momentum prompted Intuitive to forecast an increase of about 13% to 16% in da Vinci procedures worldwide in 2024. In 2023, Intuitive’s da Vinci procedure growth was 22%, as almost 2.29 million surgeries were performed with the systems. The company placed 415 da Vinci robots with customers in the fourth quarter alone, up 12% from the same period a year ago. Preliminary fourth-quarter revenue rose 17% to about $1.93 billion. William Blair analyst Brandon Vazquez said the preliminary fourth-quarter results beat expectations in nearly all categories. “The bottom line is that Intuitive is clearly heading into 2024 with strong momentum,” Vazquez said in a report to clients. Full story - Staying with Creo's growing collaboration with robotic surgery companies, notably with Intuitive, the world's largest robotic surgery company - The following, also from the above Medtechdive link, provides food for thought - At the J.P. Morgan event, Guthart declined to say whether Intuitive plans to roll out a next-generation multi-port robot in the year ahead, a topic of interest among investors. “The fact that management didn’t comment leaves open the possibility for a launch this year,” J.P. Morgan analyst Robbie Marcus said in a research note after the presentation, pointing out that the executives made clear last year a new robot would not come in 2023. |
Posted at 09/1/2024 18:38 by master investor No meetings scheduled with investor meet company. |
Posted at 02/1/2024 17:27 by parob Over 4M traded. I don't think this is just private investors loading up. |
Posted at 12/10/2023 10:36 by xxxxxy Creo Medical Group PLC Investor PresentationSource: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
